FierceBiotech Apr 3, 2026 ADCs, TCEs among ‘exciting things’ on Boehringer’s dealmaking shopping list
FierceBiotech Apr 3, 2026 Months after $100M series A, Syneron closes $150M round to support peptide platform
FierceBiotech Apr 2, 2026 UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments
FierceBiotech Apr 2, 2026 Epia Neuro launches with BCI device to help stroke patients rework brain signals
FierceBiotech Apr 2, 2026 Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest
FierceBiotech Apr 1, 2026 Valneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole story
FierceBiotech Apr 1, 2026 ‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1
FierceBiotech Apr 1, 2026 Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down